BioSpace News Archive

AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 52,250 shares of the company’s common stock to four new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Approval based on Phase 3 CheckMate -9LA trial results showing superior overall survival in patients with metastatic non-small cell lung cancer, regardless of PD-L1 expression or tumor histologies European Commission decision marks the first time

AstraZeneca’s BRILINTA ® (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). The approva

- Financing led by Ping An Capital - - Phase 2 SPARTA Trial for APL-101 Now Enrolling - - Phase 3 Clinical Trial to begin in China for APL-106 ( Uproleselan ) -

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its third quarter 2020 financial results on Tuesday, November 10, 2020. In connection with the earnings release, Gossamer’s management team will host a live conference ca

Primary Results from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session Cytokinetics to Host Investor/Media Event and Webcast Related to GALACTIC-HF Results on November 13, 2020 at 1:00 PM ET

Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, is pleased to announce positive preliminary preclinical data regarding the performance of its oral drug delivery system (DDS). The DDS capsule uses a proprietary autonomous localization technology designed to identify the ileal/ileocecal region of the GI tract. Because the DDS localizatio

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the appointment of Barbara Duncan to its Board of Directors, where she will also serve as Chair of the Audit Committee.

The platelet function test market may garner considerable growth during the assessment period of 2020-2030.

The demand within the global spinal devices market is slated to ascend in the years to follow.